About us Disease Focus Contact us

Respivert is a small molecule drug discovery company working towards the identification of new treatments for patients with Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
The more severe forms of these diseases are poorly responsive to existing therapies such as inhaled corticosteroids and new disease modifying treatments are urgently required.

Making a difference to patients with lung disease

Respivert was established in 2007 to identify a new generation of inhaled treatments for serious lung diseases.

In May 2010, RespiVert was acquired by Janssen Biotech, Inc. (formerly known as Centocor Ortho Biotech Inc.), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Respivert has continued discovery and development activities of its programmes and since inception Respivert has taken 3 novel compounds into clinical testing.


About us Disease Focus Contact us Legal Notice

© 2015 RespiVert Ltd. All rights reserved. Registered Office : 50-100 Holmers Farm Way High Wycombe HP12 4EG United Kingdom Registered in England. Registered Number: 06032131
VAT Registered Number :GB912569321